Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Services-Medical Laboratories · market cap $7M
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| Vodobatinib (K0706) capsules | Phase 2 | Healthy (For Part A) |
| SDN-037 | Phase 3 | Inflammation and Pain Associated With Ocular Surgery |
| Brimonidine Tartrate Ophthalmic Suspension | Phase 3 | Open Angle Glaucoma |
| SPARC1104 modified dose regimen I | Phase 3 | Spasticity |
| SPARC1103 low dose | Phase 2 | Spasticity |
| SPARC1203 | Phase 2 | Allergic Rhinitis |
| SPARC0913 | Phase 3 | Open Angle Glaucoma |
| SPARC1310 I | Phase 2 | Seasonal Allergic Rhinitis |
| SPARC0912 | Phase 3 | Open Angle Glaucoma |
| SPARC1316 Dose 1 | Phase 2 | Asthma |
| SPARC1102 I | Phase 2 | Allergic Conjunctivitis |
| SPARC0921 | Phase 3 | Spasticity |
Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.